Knight to Present at the 2022 BIO International Convention in San Diego
07 juin 2022 18h01 HE
|
Knight Therapeutics
MONTREAL, June 07, 2022 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) ("Knight"), a leading pan-American (ex-US) specialty pharmaceutical company, announced today that Amal Khouri, Chief...
Coya Therapeutics Secures $10 Million Financing to Advance Clinical and Pre-Clinical Pipeline of Regulatory T Cell Therapeutics
07 juin 2022 10h02 HE
|
Coya Therapeutics, Inc.
Coya Therapeutics’ clinical and biomarker data continue to demonstrate regulatory T cells (Tregs) ability to meaningfully dampen both systemic and neuroinflammation, thereby restoring the immune...
Knight to Present at the Jefferies 2022 Healthcare Conference in New York City
03 juin 2022 07h30 HE
|
Knight Therapeutics
MONTREAL, June 03, 2022 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) ("Knight") a pan-America (ex-USA) specialty pharmaceutical company, announced today that Samira Sakhia, President and...
Knight Therapeutics Assumes Commercial Activities for Exelon in Colombia
01 juin 2022 07h30 HE
|
Knight Therapeutics
MONTREAL, June 01, 2022 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) ("Knight") a pan-American (ex-USA) specialty pharmaceutical company, announced today that its Colombian affiliate,...
Compass Therapeutics to Present at the 2022 Jefferies Global Healthcare Conference
31 mai 2022 08h00 HE
|
Compass Therapeutics
BOSTON, May 31, 2022 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage biopharmaceutical company developing proprietary antibody-based therapeutics to treat cancer,...
Knight Therapeutics Enters into Exclusive License and Supply Agreements with Rigel Pharmaceuticals to Commercialize Fostamatinib in Latin America
24 mai 2022 07h30 HE
|
Knight Therapeutics
MONTREAL, May 24, 2022 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD), a pan-American (ex-USA) specialty pharmaceutical company, today announced that it has entered into exclusive license...
Knight Therapeutics Reports First Quarter 2022 Results
12 mai 2022 07h30 HE
|
Knight Therapeutics
MONTREAL, May 12, 2022 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) ("Knight" or “the Company”), a leading Pan-American (ex-US) specialty pharmaceutical company, today reported financial...
Knight Therapeutics and Helsinn Healthcare SA Enter into Exclusive License, Distribution, and Supply Agreement for Akynzeo® and Aloxi®
12 mai 2022 07h00 HE
|
Knight Therapeutics
MONTREAL and LUGANO, Switzerland, May 12, 2022 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) (“Knight”), a pan-American (ex-USA) specialty pharmaceutical company, and Helsinn Healthcare SA...
Knight to Present at the 2022 RBC Capital Markets Global Healthcare Conference in New York City
11 mai 2022 21h30 HE
|
Knight Therapeutics
MONTREAL, May 11, 2022 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) ("Knight"), a leading pan-American (ex-US) specialty pharmaceutical company, announced today that Samira Sakhia,...
Knight Therapeutics Inc. announces voting results from the Annual Meeting
11 mai 2022 21h28 HE
|
Knight Therapeutics
MONTREAL, May 11, 2022 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX:GUD) ("Knight" or the "Corporation") a leading pan-American (ex-US) specialty pharmaceutical company, announced today the...